PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Surveillance and prevention critical for Ebola control amid lack of effective prophylactics or therapeutics, says GlobalData

Following WHO reports of 53 confirmed cases, 600 suspected cases, and 139 suspected deaths from the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda;

Anaelle Tannen, Senior Infectious Disease Analyst at GlobalData, a leading intelligence and productivity platform, offers her view:

“On May 17, 2026, the WHO declared the Ebola outbreak a Public Health Emergency of International Concern (PHEIC), the highest level of alert that the organization can issue. On May 20, 2026, the WHO assessed the risk of the epidemic as high at the national and regional levels, but low at the global level. Thus, while highly serious, this is not expected to become a pandemic, with the WHO advising against the closure of international borders.

“Ebola is a highly contagious viral disease that can cause severe illness and has a high fatality rate.  Ebola viruses normally infect animals, typically fruit bats, but outbreaks among humans can sometimes start when people eat or handle infected animals. It spreads through direct contact with the body fluids of infected people or wild animals, and early symptoms often include fever, weakness, headache, vomiting, and bleeding. The virus is most commonly found in Central and West Africa.

“The specific strain causing this outbreak is known as Bundibugyo and has not been seen for over a decade. It has been involved in two previous outbreaks, in which around 30% of those affected died. Dealing with this specific strain is difficult due to a lack of effective therapies. While three antivirals and five vaccines are approved for Ebola worldwide, according to GlobalData’s Marketed Products Database, none are effective against the Bundibugyo strain. However, experts are looking into the possibility that some of these products could be deployed under emergency protocols on the basis that they may provide some degree of cross-protection against Bundibugyo.

“An additional complication is that the outbreak is taking place in a conflict zone, with a quarter of a million people displaced from their homes and people moving across borders into neighboring countries, which complicates surveillance, contact tracing, and the delivery of healthcare, further contributing to the spread of disease.

“This situation requires international coordination and cooperation to understand the extent of the outbreak, to coordinate surveillance, prevention and response efforts, and to ensure this does not become a global pandemic. Nonetheless, the risk Ebola poses outside Central and East Africa is minimal as of now.”

About GlobalData

GlobalData Plc (LSE:DATA) operates an intelligence platform that empowers leaders to act decisively in a world of complexity and change. By uniting proprietary data, human expertise, and purpose-built AI into a single, connected platform, we help organizations see what is coming, move faster, and lead with confidence. Our solutions are used by over 5,000 organizations across the world’s largest industries, providing tailored intelligence that supports strategic planning, innovation, risk management, and sustainable growth.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026